KR20030009429A - 비형 간염 코어 항원 융합 단백질 - Google Patents
비형 간염 코어 항원 융합 단백질 Download PDFInfo
- Publication number
- KR20030009429A KR20030009429A KR1020027013451A KR20027013451A KR20030009429A KR 20030009429 A KR20030009429 A KR 20030009429A KR 1020027013451 A KR1020027013451 A KR 1020027013451A KR 20027013451 A KR20027013451 A KR 20027013451A KR 20030009429 A KR20030009429 A KR 20030009429A
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- hbcag
- loop
- nucleic acid
- copies
- Prior art date
Links
- 101710132601 Capsid protein Proteins 0.000 title claims abstract description 76
- 102000037865 fusion proteins Human genes 0.000 title description 2
- 108020001507 fusion proteins Proteins 0.000 title description 2
- 208000006454 hepatitis Diseases 0.000 title description 2
- 231100000283 hepatitis Toxicity 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 97
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 93
- 239000002245 particle Substances 0.000 claims abstract description 41
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 17
- 239000000539 dimer Substances 0.000 claims abstract description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 238000002255 vaccination Methods 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229940021993 prophylactic vaccine Drugs 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 238000003780 insertion Methods 0.000 abstract description 12
- 230000037431 insertion Effects 0.000 abstract description 12
- 210000000987 immune system Anatomy 0.000 abstract description 6
- 239000000178 monomer Substances 0.000 abstract description 6
- 230000000717 retained effect Effects 0.000 abstract description 2
- 210000000234 capsid Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 description 19
- 239000000427 antigen Substances 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 239000007771 core particle Substances 0.000 description 13
- 241000700605 Viruses Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000607142 Salmonella Species 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000709721 Hepatovirus A Species 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 206010016952 Food poisoning Diseases 0.000 description 3
- 208000019331 Foodborne disease Diseases 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108010083021 Epstein-Barr virus glycoprotein 85 Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027241 Meningitis haemophilus Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241001428754 Rat leukemia virus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710192036 Sporozoite surface protein 2 Proteins 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- QPBNUBJVIBPFJM-UHFFFAOYSA-N acetic acid;1h-pyrimidine-2,4-dione Chemical compound CC(O)=O.OC1=CC=NC(O)=N1 QPBNUBJVIBPFJM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
프라이머 | 서열(5′→3′) |
123456789 | GTTACCATGGACATTGACCCTTATaGTCCATAGA(ACCACCAGA)5AACAACAGTAGTTTCCGGGTCCATAGA(ACCACCAGA)6AACAACAGTAGTTTCCGGGTCCATAGA(ACCACCAGA)7AACAACAGTAGTTTCCGGGTTGTT(GGTGGTTCT)5ATGGACATTGACCCTTATGTTGTT(GGTGGTTCT)6ATGGACATTGACCCTTATGTTGTT(GGTGGTTCT)7ATGGACATTGACCCTTATTATGAAGCTTATGAGTCCAAGGAbTATGAAGCTTCCGTCGTCAAACAAb |
aNcoI 제한 부위는 볼드체로 표시bHindIII 제한 부위는 볼드체로 표시 |
지방족 | 비-극성 | G A P |
I L V | ||
극성-비하전 | C S T M | |
N Q | ||
극성-하전 | D E | |
K R | ||
방향족 | H F W Y |
Claims (23)
- B형 간염 코어 항원(HBcAg)의 탠덤 카피를 포함하는 단백질.
- 제 1 항에 있어서, HBcAg의 두 카피의 다이머인 단백질.
- 제 1 항 또는 2 항에 있어서, HBcAg의 카피 중 하나 이상이 e1 루프에 이종 에피토프를 갖는 단백질.
- 제 3 항에 있어서, HBcAg의 모든 카피가 e1 루프에 이종 에피토프를 갖는 단백질.
- 제 4 항에 있어서, 모든 카피가 e1 루프에 동일한 이종 에피토프를 갖는 단백질.
- 제 4 항에 있어서, 각각의 카피가 e1 루프에 상이한 이종 에피토프를 갖는 단백질.
- 제 3 항 내지 6 항 중 어느 한 항에 있어서, 이종 에피토프 또는 각각의 이종 에피토프가 B형 간염 바이러스(HBV)의 pre-S1 또는 pre-S2 영역으로부터 유래되는 단백질.
- 제 3 항 내지 7 항 중 어느 한 항에 있어서, 이종 에피토프 또는 각각의 이종 에피토프가 e1 루프에 10 내지 120 아미노산 잔기로 된 이종 서열에 있는 단백질.
- 제 1 항 내지 8 항 중 어느 한 항에 있어서, HBcAg의 카피 중 하나 이상이 C-말단에서 절단되는 단백질.
- 제 1 항 내지 9 항 중 어느 한 항에 있어서, HBcAg의 탠덤 카피가 링커에 의해 결합되는 단백질.
- 제 10 항에 있어서, 링커가 적어도 1.5 nm 길이인 단백질.
- 제 10 항 또는 11 항에 있어서, 링커가 서열 GlyGlySer(GGS)의 다중 카피를 포함하는 단백질.
- 제 12 항에 있어서, 링커가 서열 GGS의 5, 6 또는 7 카피를 포함하는 단백질.
- 제 1 항 내지 13 항 중 어느 한 항에서 청구된 단백질의 다중 카피를 포함하는 입자.
- 제 1 항 내지 13 항 중 어느 한 항에서 청구된 단백질을 암호화하는 핵산 분자.
- 제 15 항에 있어서, 발현 벡터인 핵산 분자.
- 제 15 항 또는 16 항에서 청구된 핵산 분자를 포함하는 숙주 세포.
- 단백질을 암호화하는 핵산 분자를 함유하는 숙주 세포를 단백질이 발현되는 조건하에서 배양한 다음, 단백질을 회수하는 단계를 포함하는, 제 1 항 내지 13 항 중 어느 한 항에서 청구된 단백질의 생산방법.
- 제 1 항 내지 13 항 중 어느 한 항에서 청구된 단백질, 제 14 항에서 청구된 입자 또는 제 15 항 또는 16 항에서 청구된 핵산 분자 및 약학적으로 허용되는 담체 또는 희석제를 포함하는 약학 조성물.
- 인체 또는 동물체의 예방 또는 치료 백신접종법에 사용하기 위한 제 1 항 내지 13 항 중 어느 한 항에 따른 단백질, 제 14 항에 따른 입자 또는 제 15 항 또는 16 항에 따른 핵산 분자.
- HBV에 대한 인체 또는 동물체의 예방 또는 치료 백신접종법에 사용하기 위한 제 20 항에 따른 단백질, 입자 또는 핵산 분자.
- HBV에 대한 인체 또는 동물체의 예방 또는 치료 백신접종용 약제의 제조를 위한 제 1 항 내지 13 항 중 어느 한 항에 따른 단백질, 제 14 항에 따른 입자 또는 제 15 항 또는 16 항에 따른 핵산 분자의 용도.
- 제 1 항 내지 13 항 중 어느 한 항에서 청구된 단백질, 제 14 항에서 청구된 입자 또는 제 15 항 또는 16 항에서 청구된 핵산 분자를 피검자에 투여하는 단계를 포함하는, 피검자의 예방 또는 치료 백신접종법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00107118.2 | 2000-04-07 | ||
EP00107118 | 2000-04-07 | ||
PCT/GB2001/001607 WO2001077158A1 (en) | 2000-04-07 | 2001-04-09 | Hepatitis b core antigen fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030009429A true KR20030009429A (ko) | 2003-01-29 |
KR100808313B1 KR100808313B1 (ko) | 2008-02-27 |
Family
ID=8168351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027013451A KR100808313B1 (ko) | 2000-04-07 | 2001-04-09 | 비형 간염 코어 항원 융합 단백질 |
Country Status (18)
Country | Link |
---|---|
US (1) | US7270821B2 (ko) |
EP (1) | EP1268530B1 (ko) |
JP (1) | JP4713809B2 (ko) |
KR (1) | KR100808313B1 (ko) |
CN (1) | CN100360556C (ko) |
AP (1) | AP1836A (ko) |
AT (1) | ATE336502T1 (ko) |
AU (1) | AU784345B2 (ko) |
BR (1) | BR0109919A (ko) |
CA (1) | CA2405438C (ko) |
DE (1) | DE60122300T2 (ko) |
DK (1) | DK1268530T3 (ko) |
EA (1) | EA200201077A1 (ko) |
ES (1) | ES2269371T3 (ko) |
MX (1) | MXPA02009895A (ko) |
PT (1) | PT1268530E (ko) |
WO (1) | WO2001077158A1 (ko) |
ZA (1) | ZA200208967B (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100465643B1 (ko) * | 2001-09-28 | 2005-01-13 | (주) 에이프로젠 | 비형 간염 바이러스 프리에쓰1 항원 유래의 에피토프 태그및 이에 대한 항체를 이용한 폴리펩티드의 검출 및 정제방법 |
KR100687653B1 (ko) * | 2005-05-13 | 2007-02-27 | 유기현 | 스타-델타 결선용 전자개폐기의 제어방법 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003511075A (ja) * | 1999-10-08 | 2003-03-25 | セルテック ファーマ ユアロップ リミテッド | 免疫原の設計 |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
BR0213117A (pt) | 2001-10-05 | 2004-09-21 | Cytos Biotechnology Ag | Conjugados peptìdeo angiotensina-veìculo e seus usos |
US6932971B2 (en) | 2002-07-18 | 2005-08-23 | Cytos Biotechnology Ag | Hapten-carrier conjugates and uses thereof |
CA2492930C (en) | 2002-07-19 | 2013-01-08 | Cytos Biotechnology Ag | Vaccine compositions containing amyloid beta1-6 antigen arrays |
KR20050115913A (ko) | 2003-03-26 | 2005-12-08 | 사이토스 바이오테크놀로지 아게 | Melan―a 펩티드 유사체-바이러스-양-입자컨쥬게이트 |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
CN100537762C (zh) * | 2004-06-24 | 2009-09-09 | 中国人民解放军军事医学科学院野战输血研究所 | 一种嵌合型病毒样颗粒疫苗载体蛋白及其制备方法与应用 |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
WO2009130588A2 (en) * | 2008-04-22 | 2009-10-29 | Tripep Ab | Immunogen platform |
MX337723B (es) | 2008-12-09 | 2016-03-15 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige. |
MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
EP2865752A1 (en) | 2009-09-03 | 2015-04-29 | Pfizer Vaccines LLC | PCSK9 vaccine |
GB0918679D0 (en) * | 2009-10-23 | 2009-12-09 | Iqur Ltd | Influenza vaccine |
EP2547695B1 (en) | 2010-03-16 | 2018-05-09 | Biontech Protein Therapeutics GmbH | Tumor vaccination involving a humoral immune response against self-protein cldn18.2 |
EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
CN102199217B (zh) * | 2011-04-01 | 2013-03-27 | 中国人民解放军第三军医大学 | 乙型肝炎病毒多表位融合蛋白及其制备方法和应用 |
US9446120B2 (en) | 2011-04-15 | 2016-09-20 | Osaka University | DNA vaccine |
JP6422022B2 (ja) * | 2012-08-31 | 2018-11-14 | 国立大学法人大阪大学 | Vegf及び/又はアンギオポエチン−2の特異的エピトープを含むdnaワクチン |
JP6518193B2 (ja) * | 2012-12-11 | 2019-05-22 | オシバ、ソシエテ、パル、アクシオン、シンプリフィエOsivax Sas | 改善された特性を有する改変コイルドコイル型タンパク質 |
EP3004173B1 (en) * | 2013-06-06 | 2018-05-30 | iQur Limited | Single domain antibody display |
CN104341506A (zh) * | 2013-07-30 | 2015-02-11 | 复旦大学 | 一种重组融合蛋白及其用途 |
EP3104877B1 (en) | 2014-02-11 | 2020-01-22 | The USA, as represented by The Secretary, Department of Health and Human Services | Pcsk9 vaccine and methods of using the same |
GB201402890D0 (en) | 2014-02-18 | 2014-04-02 | Iqur Ltd | Vaccines based on hepatitis B Core antigens |
GB201421692D0 (en) * | 2014-12-05 | 2015-01-21 | Iquar Ltd | Vaccines based on hepatitis B core antigens |
GB201505041D0 (en) * | 2015-03-25 | 2015-05-06 | Iqur Ltd | Vaccines based on hepatitis B core antigens |
WO2018089814A1 (en) | 2016-11-11 | 2018-05-17 | Fraunhofer Usa, Inc. | Covalently fused viral coat proteins for the display of target molecules |
CN110343707B (zh) * | 2019-05-30 | 2021-06-15 | 中国科学院生物物理研究所 | 基于乙肝核心抗原的hsv分型用蛋白、试剂盒及方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2480780B1 (fr) * | 1980-04-22 | 1985-12-06 | Pasteur Institut | Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn |
JP2514033B2 (ja) * | 1987-05-20 | 1996-07-10 | 財団法人 癌研究会 | B型肝炎ウィルスの複製を可能とする新規な培養細胞 |
NZ235315A (en) * | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
US5723129A (en) * | 1991-10-16 | 1998-03-03 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
JPH06279500A (ja) * | 1992-09-30 | 1994-10-04 | Imuno Japan:Kk | HBc融合蛋白粒子およびその製造方法 |
WO1997035008A1 (en) * | 1996-03-21 | 1997-09-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods and compositions of chimeric polypeptides for tumor antigen vaccines |
US20030021804A1 (en) * | 1997-01-21 | 2003-01-30 | Philip Needleman | Immunological process for increasing the hdl cholestrol concentration |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
US6180343B1 (en) * | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
JP2003511075A (ja) * | 1999-10-08 | 2003-03-25 | セルテック ファーマ ユアロップ リミテッド | 免疫原の設計 |
US20040054139A1 (en) * | 2000-06-22 | 2004-03-18 | Mark Page | Modification of hepatitis b core antigen |
US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
-
2001
- 2001-04-09 US US10/240,917 patent/US7270821B2/en not_active Expired - Fee Related
- 2001-04-09 JP JP2001575628A patent/JP4713809B2/ja not_active Expired - Fee Related
- 2001-04-09 BR BR0109919-1A patent/BR0109919A/pt not_active IP Right Cessation
- 2001-04-09 AU AU46706/01A patent/AU784345B2/en not_active Ceased
- 2001-04-09 DE DE60122300T patent/DE60122300T2/de not_active Expired - Lifetime
- 2001-04-09 AT AT01919645T patent/ATE336502T1/de active
- 2001-04-09 ES ES01919645T patent/ES2269371T3/es not_active Expired - Lifetime
- 2001-04-09 AP APAP/P/2002/002658A patent/AP1836A/en active
- 2001-04-09 CA CA2405438A patent/CA2405438C/en not_active Expired - Fee Related
- 2001-04-09 MX MXPA02009895A patent/MXPA02009895A/es active IP Right Grant
- 2001-04-09 DK DK01919645T patent/DK1268530T3/da active
- 2001-04-09 PT PT01919645T patent/PT1268530E/pt unknown
- 2001-04-09 KR KR1020027013451A patent/KR100808313B1/ko not_active IP Right Cessation
- 2001-04-09 EP EP01919645A patent/EP1268530B1/en not_active Expired - Lifetime
- 2001-04-09 EA EA200201077A patent/EA200201077A1/ru unknown
- 2001-04-09 WO PCT/GB2001/001607 patent/WO2001077158A1/en active IP Right Grant
- 2001-04-09 CN CNB018106889A patent/CN100360556C/zh not_active Expired - Fee Related
-
2002
- 2002-11-05 ZA ZA200208967A patent/ZA200208967B/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100465643B1 (ko) * | 2001-09-28 | 2005-01-13 | (주) 에이프로젠 | 비형 간염 바이러스 프리에쓰1 항원 유래의 에피토프 태그및 이에 대한 항체를 이용한 폴리펩티드의 검출 및 정제방법 |
KR100687653B1 (ko) * | 2005-05-13 | 2007-02-27 | 유기현 | 스타-델타 결선용 전자개폐기의 제어방법 |
Also Published As
Publication number | Publication date |
---|---|
JP2003530123A (ja) | 2003-10-14 |
AU4670601A (en) | 2001-10-23 |
AP2002002658A0 (en) | 2002-12-31 |
EA200201077A1 (ru) | 2003-04-24 |
ES2269371T3 (es) | 2007-04-01 |
ATE336502T1 (de) | 2006-09-15 |
EP1268530B1 (en) | 2006-08-16 |
CA2405438A1 (en) | 2001-10-18 |
DK1268530T3 (da) | 2006-11-13 |
CN100360556C (zh) | 2008-01-09 |
MXPA02009895A (es) | 2004-09-06 |
KR100808313B1 (ko) | 2008-02-27 |
AU784345B2 (en) | 2006-03-16 |
US20040223965A1 (en) | 2004-11-11 |
US7270821B2 (en) | 2007-09-18 |
DE60122300T2 (de) | 2007-08-30 |
BR0109919A (pt) | 2003-03-11 |
JP4713809B2 (ja) | 2011-06-29 |
ZA200208967B (en) | 2003-10-08 |
WO2001077158A1 (en) | 2001-10-18 |
EP1268530A1 (en) | 2003-01-02 |
CN1441807A (zh) | 2003-09-10 |
DE60122300D1 (de) | 2006-09-28 |
CA2405438C (en) | 2011-07-12 |
AP1836A (en) | 2008-03-14 |
PT1268530E (pt) | 2006-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100808313B1 (ko) | 비형 간염 코어 항원 융합 단백질 | |
CA2413546C (en) | Modification of hepatitis b core antigen | |
US9801927B2 (en) | Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof | |
AU2001266163A1 (en) | Modification of hepatitis B core antigen | |
EP0563093A1 (en) | A composition used as a therapeutic agent against chronic viral hepatic diseases | |
Nassal et al. | A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula | |
JPH06509237A (ja) | ワクチンとしてのネコ白血病ウィルスgp70からの融合蛋白質 | |
IL167886A (en) | Viral recombinant pseudo-particles, compositions comprising them and uses thereof | |
JPH02223594A (ja) | ヒトライノウイルスペプチド | |
EP0328390B1 (en) | Peptide treatment of refractory infectious diseases | |
Wang et al. | A novel virus-like particle based on hepatitis B core antigen and substrate-binding domain of bacterial molecular chaperone DnaK | |
Green | The development and use of antigen-antibody-LTB (Ag-MAb-LTB) complexes as immunogens | |
Found | Equine herpes virus-4 thymidine-kinase-vaccine; expression in mammal host transformant; DNA sequence; potential mono-valent, multivalent live recombinant vaccine vector |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130207 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140213 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150213 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160212 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170209 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180209 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |